Displaying drugs 2476 - 2500 of 3590 in total
ORE-1001
ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.
Investigational
NCX-1000
NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).
Investigational
DRF-1042
Investigational
G100
Investigational
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
TSHA-104
Investigational
IBIO-100
IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.
Investigational
TSHA-101
Investigational
MDX-1097
MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
Investigational
TSHA-102
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
AOC-1020
AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational
CRA_10433
Experimental
ADX-10061
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Investigational
Matched Iupac: … (5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol …
ONCOS‐102
Investigational
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
BN104
Investigational
KB105
Investigational
Poloxamer 331
Investigational
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
RG-4733
Ro4929097 has been used in trials studying the treatment of Sarcoma, LYMPHOMA, Neoplasms, Wilm's Tumor, and OSTEOSARCOMA, among others.
Investigational
Matched Iupac: … 2,2-dimethyl-N'-[(10S)-9-oxo-8-azatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,11,13-hexaen-10-yl]-N- …
Anti-SARS-CoV-2 REGN-COV2
Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered...
Investigational
lambda-bis(2,2'-bipyridine)-(5-methyl-2-2'-bipyridine)-C9-adamantane ruthenium (II)
Experimental
Matched Iupac: … ',8''-spiroter[tricyclo[7.4.0.0^{2,7}]tridecane]-1,1',1'',3,3',3'',5,5',5'',10,10',10'',12,12',12''-pentadecaene ... 12-(8-{[(1R,3S,5R,7S)-adamantan-2-yl]carbamoyl}octyl)-4-methyl-7,7',7'',9,9',9''-hexaaza-8-ruthena-8,8 …
Iron polymaltose
Experimental
Matched Products: … FERLOS 20 MG/ML ORAL ÇÖZELTİ, 10 ADET ... VEGAFERON 100 MG/5 ML ORAL ÇÖZELTİ, 10 ADET ... FERTAMİR 40 MG EFERVESAN GRANÜL İÇEREN SAŞE, 10 SAŞE …
Displaying drugs 2476 - 2500 of 3590 in total